Strategic Financial Services Has Upped General Electric Co. (GE) Stake By $679,320; Achillion Pharmaceuticals (ACHN) Shorts Lowered By 18.34%

January 17, 2018 - By Henry Gaston

Strategic Financial Services Inc increased General Electric Co. (GE) stake by 13.14% reported in 2017Q3 SEC filing. Strategic Financial Services Inc acquired 28,305 shares as General Electric Co. (GE)’s stock declined 7.64%. The Strategic Financial Services Inc holds 243,655 shares with $5.89 million value, up from 215,350 last quarter. General Electric Co. now has $151.63B valuation. The stock decreased 3.98% or $0.725 during the last trading session, reaching $17.485. About 59.63 million shares traded. General Electric Company (NYSE:GE) has declined 4.46% since January 17, 2017 and is downtrending. It has underperformed by 21.16% the S&P500.

Achillion Pharmaceuticals Incorporated (NASDAQ:ACHN) had a decrease of 18.34% in short interest. ACHN’s SI was 7.06 million shares in January as released by FINRA. Its down 18.34% from 8.64 million shares previously. With 3.15M avg volume, 2 days are for Achillion Pharmaceuticals Incorporated (NASDAQ:ACHN)’s short sellers to cover ACHN’s short positions. The SI to Achillion Pharmaceuticals Incorporated’s float is 7.72%. The stock decreased 1.37% or $0.04 during the last trading session, reaching $2.89. About 225,539 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 47.61% since January 17, 2017 and is downtrending. It has underperformed by 64.31% the S&P500.

Investors sentiment decreased to 0.69 in Q3 2017. Its down 0.10, from 0.79 in 2017Q2. It fall, as 112 investors sold GE shares while 818 reduced holdings. 118 funds opened positions while 525 raised stakes. 4.70 billion shares or 1.82% more from 4.61 billion shares in 2017Q2 were reported. Amica Retiree Medical Tru, Rhode Island-based fund reported 55,979 shares. Lazard Asset Limited Liability Company has 0.25% invested in General Electric Company (NYSE:GE). Cibc World Markets Corporation owns 1.51M shares for 0.35% of their portfolio. Chesley Taft And Limited Liability has 1.04% invested in General Electric Company (NYSE:GE). State Treasurer State Of Michigan holds 2.74M shares. Patten Gru holds 313,115 shares or 0.33% of its portfolio. 57,615 were accumulated by Fairfield Bush &. Mark Sheptoff Financial Planning Ltd Liability Corp, Connecticut-based fund reported 21,194 shares. Brave Asset Mgmt Inc holds 1.2% of its portfolio in General Electric Company (NYSE:GE) for 94,714 shares. Northpointe Capital Ltd Liability accumulated 182,038 shares. Alphamark Limited Co holds 0.02% or 1,953 shares. Valley National Advisers holds 1.34% of its portfolio in General Electric Company (NYSE:GE) for 161,952 shares. Nuveen Asset Mngmt accumulated 577,774 shares or 0.09% of the stock. Wg Shaheen And Assoc Dba Whitney And stated it has 182,421 shares. 1.93 million are held by Old Republic Corporation.

Since August 8, 2017, it had 2 insider buys, and 1 sale for $4.48 million activity. Flannery John Leonard bought $2.66 million worth of stock. $2.46 million worth of General Electric Company (NYSE:GE) was bought by TISCH JAMES S. Shares for $633,375 were sold by Comstock Elizabeth J on Wednesday, August 9.

Among 26 analysts covering General Electric Company (NYSE:GE), 10 have Buy rating, 5 Sell and 11 Hold. Therefore 38% are positive. General Electric Company had 81 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by S&P Research with “Buy” on Monday, August 17. Bank of America downgraded the stock to “Neutral” rating in Wednesday, April 26 report. The firm earned “Buy” rating on Monday, October 23 by RBC Capital Markets. As per Tuesday, October 24, the company rating was downgraded by Oppenheimer. The rating was upgraded by Langenberg on Monday, November 13 to “Buy”. The firm earned “Hold” rating on Thursday, March 23 by BMO Capital Markets. Bank of America maintained the stock with “Buy” rating in Tuesday, November 14 report. RBC Capital Markets maintained General Electric Company (NYSE:GE) rating on Monday, January 25. RBC Capital Markets has “Outperform” rating and $33 target. Bank of America upgraded it to “Buy” rating and $27.0 target in Monday, October 23 report. As per Thursday, December 28, the company rating was maintained by Tigress Financial.

Among 10 analysts covering Achillion Pharma (NASDAQ:ACHN), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Achillion Pharma had 24 analyst reports since August 13, 2015 according to SRatingsIntel. Chardan Capital Markets upgraded it to “Neutral” rating and $5 target in Friday, November 4 report. The rating was maintained by Leerink Swann with “Buy” on Monday, December 11. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Market Perform” rating by Leerink Swann on Friday, January 29. The company was upgraded on Tuesday, September 8 by UBS. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Hold” rating by Jefferies on Wednesday, September 9. On Thursday, July 14 the stock rating was initiated by Chardan Capital Markets with “Sell”. Robert W. Baird maintained Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Monday, September 11 with “Hold” rating. Robert W. Baird downgraded the shares of ACHN in report on Thursday, August 10 to “Neutral” rating. FBR Capital initiated Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Thursday, September 15 with “Outperform” rating. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Outperform” rating by Leerink Swann on Thursday, May 18.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $398.41 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts